Oncologist use and perception of large panel next-generation tumor sequencing.

ABSTRACT:

Background

Genomic profiling is increasingly incorporated into oncology research and the clinical care of cancer patients. We sought to determine physician perception and use of enterprise-scale clinical sequencing at our center, including whether testing changed management and the reasoning behind this decision-making.

Patients and methods

All physicians who consented patients to MSK-IMPACT, a next-generation hybridization capture assay, in tumor types where molecular profiling is not routinely performed were asked to complete a questionnaire for each patient. Physician determination of genomic 'actionability' was compared to an expertly curated knowledgebase of somatic variants. Reported management decisions were compared to chart review.

Results

Responses were rece

SUBMITTER: Schram AM 

PROVIDER: S-EPMC5834089 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature